gentle
Building the future of mental health and wellness
The next generation of neuromodulation for scalable care.
gentle is pursuing regulatory approval beginning in Q2 2026, starting with depression, anxiety, sleep, and adhd related indications.
gentle
Building the future of mental health and wellness.
gentle’s clinical platform is built on established, cleared, and reimbursable neuromodulation techniques.
Across the United States, Europe, Canada and Australia, non-invasive stimulation modalities are cleared for clinical use and reimbursed through existing healthcare systems. These approaches have been extensively studied and are used today for depression, anxiety, and insomnia.
gentle applies these modalities within a modern, software-driven platform designed for scalability, usability, and future regulated deployment.
This timeline is not approved or approved by the FDA or any other regulating entity. These are simply internal projections.
Condition
Modality
We've shipped life-changing results with our early prototypes.
/5
Real stories and real relief.
gentle
Non-invasive neuromodulation modalities such as tDCS has been studied extensively and are generally well tolerated. Reported adverse events are typically mild and transient, including sensations such as tingling or skin irritation at electrode sites.
These safety characteristics have supported their use in both clinical and at-home settings for depression, and anxiety.